tiprankstipranks
Trending News
More News >
Fiji Kava Limited (AU:CCO)
ASX:CCO
Australian Market
Advertisement

Fiji Kava Limited (CCO) AI Stock Analysis

Compare
11 Followers

Top Page

AU:CCO

Fiji Kava Limited

(Sydney:CCO)

Rating:36Underperform
Price Target:
The overall stock score reflects significant revenue growth overshadowed by critical financial weaknesses, including negative equity and ongoing losses. Technical analysis is inconclusive due to insufficient data, and valuation metrics highlight the company's current financial struggles.

Fiji Kava Limited (CCO) vs. iShares MSCI Australia ETF (EWA)

Fiji Kava Limited Business Overview & Revenue Model

Company DescriptionThe Calmer Co International Limited operates as a medicinal kava health and wellness company in Australia, New Zealand, Fiji, and the United States. It produces and sells noble kava extract capsules, and powder mixes under the Fiji Kava and Taki Mai brand names. The company also sells its products through fijikava.com. The company was formerly known as Fiji Kava Limited and changed its name to The Calmer Co International Limited in April 2023. The Calmer Co International Limited was incorporated in 2014 and is based in West End, Australia.
How the Company Makes MoneyFiji Kava Limited generates revenue primarily through the sale of its kava-based products, which are distributed both online and through retail channels. The company's revenue streams include direct consumer sales via its e-commerce platform, partnerships with health and wellness retailers, and international distribution agreements. Additionally, Fiji Kava leverages strategic partnerships with Fijian farmers and local communities to ensure a sustainable supply chain, which helps in maintaining product quality and enhancing the brand's authenticity.

Fiji Kava Limited Financial Statement Overview

Summary
Fiji Kava Limited shows strong revenue growth but suffers from poor profitability and financial instability. The company's negative equity and persistent net losses are significant concerns. Although there are slight improvements in cash flow management, the overall financial health remains weak.
Income Statement
35
Negative
Fiji Kava Limited has experienced significant revenue growth, increasing from $1.78 million in 2023 to $4.26 million in 2024. However, profitability remains a challenge with negative net and gross profit margins, and consistent net losses across years indicate poor bottom-line performance. Negative EBIT and EBITDA margins further highlight ongoing operational inefficiencies.
Balance Sheet
20
Very Negative
The company has negative stockholders' equity, which is concerning as it indicates liabilities exceed assets, reflecting financial instability. The debt-to-equity ratio is not interpretable due to negative equity, and the equity ratio is likewise unfavorable. This precarious financial position poses significant risks to stakeholders.
Cash Flow
40
Negative
Despite negative free cash flow, there is an improvement in operating cash flow from -$3.80 million in 2023 to -$2.08 million in 2024, suggesting some progress in cash management. However, free cash flow remains negative, indicating ongoing challenges in generating sufficient cash to cover expenses and investments.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue4.26M1.78M2.08M1.16M758.87K
Gross Profit2.05M-1.40M665.97K404.43K184.33K
EBITDA-3.34M-4.86M-5.72M-3.19M-3.56M
Net Income-3.73M-5.24M-5.46M-3.39M-3.81M
Balance Sheet
Total Assets4.33M3.24M4.79M3.60M2.95M
Cash, Cash Equivalents and Short-Term Investments1.10M462.15K799.22K1.18M1.43M
Total Debt2.21M2.35M1.08M125.00K750.38K
Total Liabilities4.80M3.32M2.51M694.78K1.56M
Stockholders Equity-466.84K-87.53K2.28M2.91M1.38M
Cash Flow
Free Cash Flow-2.19M-3.82M-7.10M-4.40M-3.67M
Operating Cash Flow-2.08M-3.80M-6.14M-4.14M-3.54M
Investing Cash Flow-116.97K-21.08K-964.94K-259.37K-135.57K
Financing Cash Flow2.83M3.47M6.03M4.16M2.79M

Fiji Kava Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
$26.91B15.40-4.43%2.85%1.05%4.97%
42
Neutral
AU$5.10M-76.28%5.01%74.84%
36
Underperform
AU$9.03M-548.03%192.34%68.06%
€2.88M
34
Underperform
AU$8.86M-105.17%-3.82%51.47%
AU$5.99M
31
Underperform
AU$4.23M
-16.29%58.77%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:CCO
Fiji Kava Limited
0.01
0.00
0.00%
DE:0EG0
Health and Plant Protein Group Limited
0.01
0.00
0.00%
AU:EVE
EVE Health Group Limited
0.04
0.01
33.33%
AU:BFC
Beston Global Food Company Ltd
0.01
0.00
0.00%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
>-0.01
-33.33%
AU:OMG
Forbidden Foods Ltd
0.01
0.00
0.00%

Fiji Kava Limited Corporate Events

Director Increases Stake in The Calmer Co International Limited
Jul 25, 2025

The Calmer Co International Limited has announced a change in the director’s interest, specifically involving John Homewood. Mr. Homewood, through his associations with Homewood Venture Capital Pty Ltd and Ace Property Holdings Pty Ltd, has increased his holdings of Fully Paid Ordinary Shares (FPOS) by acquiring 13,527,825 shares, bringing the total to 133,527,825 FPOS. This acquisition was made through an on-market trade at a value of $0.003 per share. The change in Mr. Homewood’s interest could potentially impact the company’s market perception and stakeholder confidence, as it reflects a significant increase in his investment in the company.

The Calmer Co. Achieves Record Revenue and Expands US Market Presence
Jul 2, 2025

The Calmer Co. International Limited has achieved a significant milestone with its FY25 revenue surpassing AU$8 million, marking an 86% increase from the previous year. This growth is attributed to a strong multichannel strategy and the successful expansion of its product offerings, including the launch of new flavoured Taki Mai Kava Shots on Amazon USA. The company’s strategic focus on the US market is further supported by increasing brand share and customer loyalty on Amazon, as well as partnerships to enter the US kava bar market, positioning it for continued growth and market leadership.

The Calmer Co. Expands Global Reach with Natural Relaxation Products
Jun 25, 2025

The Calmer Co. International Limited is capitalizing on the global demand for natural relaxation and sleep aids by expanding its product offerings and distribution channels. The company’s commitment to a transparent supply chain and its strategic partnerships in key markets are expected to enhance its market position and provide growth opportunities. This expansion is likely to have a positive impact on its operations and strengthen its industry standing.

The Calmer Co. Expands U.S. Presence with Taki Mai Kava Tinctures on Amazon
Jun 23, 2025

The Calmer Co. has launched its Taki Mai kava tinctures on Amazon USA, marking a significant step in its expansion into the U.S. market. These tinctures, available in 1oz and 4oz bottles, are designed for modern wellness consumers and can be used directly or mixed into beverages. The launch positions The Calmer Co. as a leader in the growing kava category, with the Amazon tincture market valued at over US$11.16 million and growing at 18% annually. The company anticipates significant revenue growth from the U.S. market, which currently contributes 29% of its revenue, and aims to capitalize on the increasing demand for kava products.

The Calmer Co. Expands Fiji Kava® Distribution to Woolworths Across Australia
Jun 16, 2025

The Calmer Co. International Limited has announced the launch of its Fiji Kava® 50g Instant Kava product in Woolworths supermarkets across Australia, excluding the Northern Territory. This expansion into Woolworths, Australia’s largest supermarket chain, builds on the company’s existing presence in Coles and reinforces its leadership in the functional relaxation and natural alternatives to alcohol category. The move is a significant step in The Calmer Co’s omnichannel growth strategy, which aims to expand its reach across Australia, the USA, and the Pacific Islands, highlighting strong consumer demand for kava-based solutions.

The Calmer Co. Issues New Shares Amid Compliance Assurance
May 29, 2025

The Calmer Co International Limited has issued 37,500 fully paid ordinary shares following the exercise of options, as per the Corporations Act 2001. This move, authorized by the company’s Board of Directors, reflects compliance with relevant legal provisions and indicates no excluded information is required to be disclosed. This issuance could impact the company’s financial structure and stakeholder interests.

The Calmer Co. Expands Kava Product Distribution in Coles Supermarkets
May 25, 2025

The Calmer Co. International Limited has announced a significant expansion in the distribution of its flagship kava products, Taki Mai Kava-shot and FijiKava Instant Kava, in Coles Supermarkets across Australia. The Taki Mai Kava-shot is now available in 797 stores, and the FijiKava Instant Kava is in 801 stores, reflecting a 59% and 170% increase in store coverage, respectively. This expansion is driven by the growing consumer demand for natural wellness products that offer functional alternatives to alcohol. The company views this growth as a validation of its strategy and leadership in the kava market, further strengthening its brand presence in the Australian retail channel.

Director’s Interest Change at The Calmer Co International Limited
May 20, 2025

The Calmer Co International Limited has announced a change in the director’s interest notice, specifically regarding John Homewood. Homewood Venture Capital Pty Ltd and Ace Property Holdings Pty Ltd, both associated with Mr. Homewood, have increased their holdings in the company through the acquisition of additional fully paid ordinary shares and options. This change reflects an allocation of shares and options pursuant to a rights offer, potentially impacting the company’s market positioning by increasing insider holdings.

The Calmer Co International Limited Announces New Securities Quotation
May 19, 2025

The Calmer Co International Limited has announced the quotation of new securities on the Australian Securities Exchange (ASX). The company will be quoting 75,666,667 ordinary fully paid shares and 37,833,335 options expiring on June 30, 2026. This move is part of previously announced transactions and may impact the company’s market presence by potentially increasing liquidity and investor interest.

The Calmer Co. Completes $1M Rights Issue to Fuel Expansion
May 16, 2025

The Calmer Co. International Limited has successfully completed its renounceable rights issue, raising $1,000,713 before costs. This capital will be allocated towards capital expenditure, inventory expansion, marketing, brand promotion, and general working capital. The company’s directors and management have shown strong commitment by participating in the rights issue, reflecting confidence in the company’s future. The issuance of new shares and options is scheduled for May 16, 2025, with Mahe Capital Pty Ltd acting as the lead manager and underwriter.

The Calmer Co. Sees 104% Growth in USA Amazon Sales
May 7, 2025

The Calmer Co. International Limited reported a significant 104% year-on-year increase in its USA Amazon sales for April 2025, reaching AUD$203,000. This growth is attributed to the strong performance of its Taki Mai traditional kava brand, which accounted for 24% of the sales, and a notable rise in subscription sales, making up 28% of the total sales volume. The company is strategically expanding its presence in the U.S. market by focusing on both its instant kava brand, Fiji Kava, and its heritage brand, Taki Mai, to capture different market segments. This expansion is part of a broader strategy to launch new products and invest in R&D for long-term success.

The Calmer Co. Expands US Market Reach with Leilo Partnership
May 7, 2025

The Calmer Co. International Limited has signed a non-binding Memorandum of Understanding with Leilo, a leading US functional beverage company, to supply high-grade noble kava powders from the South Pacific to US kava bars. This partnership aims to expand The Calmer Co.’s presence in the North American market, leveraging its expertise in kava supply and supporting the growing demand for non-alcoholic beverages. The collaboration is expected to enhance the company’s market positioning and provide a stable supply chain for Leilo’s kava bar partners, potentially leading to a formal long-term supply agreement.

Fiji Kava Positioned for Growth Amidst Expanding Kava Market
May 2, 2025

The global kava root extract market is projected to grow significantly, reaching USD 5.6 billion by 2033, driven by the food and beverage industry’s growth, increased use in cosmetics and personal care, and extensive R&D activities. This growth presents opportunities for Fiji Kava Limited to enhance its market positioning and expand its operations, benefiting stakeholders by tapping into the rising demand for natural relaxation products.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 08, 2025